Symptoms: Chemotherapy-Induced Peripheral Neuropathy

Area of Science:

• Oncology
• Neuroscience
• Pharmacology

Background:

• Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating treatment toxicity.
• CIPN negatively affects patient quality of life and can limit curative cancer therapy.
• Breast cancer patients are particularly susceptible due to common causative agents.

Purpose of the Study:

• To provide a comprehensive overview of CIPN.
• To review current knowledge on CIPN predictors, pathophysiology, and management.
• To highlight ongoing research for better prediction and prevention strategies.

Main Methods:

• Literature review of CIPN pathophysiology and therapeutic agents.
• Analysis of clinical predictors, frequency, and quality of life impacts.
• Discussion of ongoing clinical and translational research in CIPN.

Main Results:

• CIPN presents significant challenges in oncology clinical practice due to its frequency and potential irreversibility.
• Multiple chemotherapy agents used in breast cancer treatment are associated with CIPN.
• Current research focuses on optimizing assessment, identifying host-specific predictors (genetics, race), and understanding CIPN's impact on treatment decisions.

Conclusions:

• Effective management and prevention of CIPN are crucial for maintaining patient quality of life and treatment adherence.
• Further research is needed to refine prediction models and develop targeted interventions for CIPN.
• Understanding individual patient factors is key to personalizing CIPN risk assessment and management.